|
[1]
|
Montoya JG,Rosso F. Is combination therapy indicated for invasive fungal infections?Yes and no[J].Curr Opin Infect Dis,2006,19(4):371-379. |
|
[2]
|
Nivoix Y,Zamfir A,Lutun P,et al,Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections[J].J Infect,2006,52(1):67-74. |
|
[3]
|
Kontoyiannis DP,Lewis RE.Combination chemotherapy for invasive fungal infections:what laboratory and clinical studies tell us so far[J].Drug Resist Updat,2003,6(1):257-269. |
|
[4]
|
Mukherjee PK,Sheehan DJ,Hitchcock CA,et al.Combination treatment of invasive fungal infections[J].Clin Microbiol Rev,2005,18(1):163-194. |
|
[5]
|
Chamilos G,Kontoyiannis DP.The rationale of combination antifungal therapy in severely immuncompromised patients:empiricism versus evidence-based medicine[J].Curr Opin Infect Dis,2006,19(4):380-385. |
|
[6]
|
Marr KA,Boeckh M,Carter RA,et al.Combination antifungal therapy for invasive aspergillosis[J].Clin Infect Dis,2004,39(6):797-802. |
|
[7]
|
Matsuoka S, Murata M. Cholesterol markedly reduces ion permeability induced by membrane-bound amphotericin B[J]. Biochim Biophys Acta, 2002,1564(2):429-434. |
|
[8]
|
Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity:a review[J]. J Chemother, 2000,12(6):463-470. |
|
[9]
|
Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures:animal experiments and clinical study[J]. J Infect Dis 2002,186(3):379-388. |
|
[10]
|
Louie A, Kaw P, Banerjee P,et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis[J].Antimicrob Agents Chemother, 2001, 45(2):485-494. |
|
[11]
|
Samaranayake YH, Samaranayake LP, Yeung KW. Evaluation of polyene-azole antagonism in liquid cultures of Candida albicans using an automated turbidometric method[J].Chemotherapy, 2001, 47(4):279-291. |
|
[12]
|
Barchiesi F, Schimizzi AM, Caselli F,et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans[J].Antimicrob Agents Chemother, 2000, 44(9):2435-2441. |
|
[13]
|
Popp AI, White MH, Quadri T,et al. Amphotericin B with and without itraconazole for invasive aspergillosis. A three-year retrospective study[J].Int J Infect Dis, 1999, 3(3):157-160. |
|
[14]
|
Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species[J].MedMycol, 2001, 39(1):91-95. |
|
[15]
|
Rodero L, Cordoba S, Cahn, P,et al. In vitro susceptibility studies of Cryptococcus Neoformans isolated from patients with no clinical response to amphotericin B therapy[J].J Antimicrob Chemother,2000, 45(2):239-242. |
|
[16]
|
Perfect JR, Dismukes WE, Dromer F,et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322. |
|
[17]
|
Sevtap Arikan, Mario Lozano-Chiu,Victor Paetznick, et al.In vitro synergy of caspofungin and amphotericin B Against Aspergillus and Fusarium spp[J].Antimicrob Agents Chemother,2002, 46(1):245-247. |
|
[18]
|
Jon AO, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin[J]. Antimicrob Agents Chemother,2005, 49 (12):4895-4902. |
|
[19]
|
Francesco B,Elisabetta S,Serena T, et al.Caspofungin in combination with amphotericin B against Candida parapsilosis[J]. Antimicrob Agents Chemoth, 2007, 51(3):941-945. |
|
[20]
|
Ogita A, Hirooka K, Yamamoto Y, et al. Synergistic fungicidal activity of Cu2+ and allicin, an allyl sulfur compound from garlic, and its relation to the role of alkyl hydroperoxide reductase 1 as a cell surface defense in Saccharomyces cerevisiae[J]. Toxicology,2005,215(3):205-13. |
|
[21]
|
Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation[J]. J Proteome Res,2009,8(11):5296-304. |
|
[22]
|
An M, Shen H, Cao Y, et al.Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans[J]. Int J Antimicrob Agents. 2009; 33(3):258-63. |
|
[23]
|
Cao YY,Dai BD, Wang Y, et al.In vitro activity of baicalein against Candida albicans biofilms[J]. Int J Antimicrob Agents, 2008,32:73-77. |
|
[24]
|
Huang S, Cao YY, Dai BD, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.Biol Pharm Bull, 2011,31:2234-2236. |
|
[25]
|
Fu ZJ, Lu H,Zhu ZY, et al.Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis[J].Biol Pharm Bull,2011,34(2):214-218. |
|
[26]
|
Phillips AJ, Sudbery I, Ramsdale M.Apoptosis induced by environmental stresses and amphotericin B in Candida albicans[J]. Proc Natl Acad Sci,2003,100:14327-14332. |
|
[27]
|
Phillips AJ, Crowe JD, Ramsdale M.Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans[J].Proc Natl Acad Sci,2006,103:726-731. |
|
[28]
|
Cao YY,HuangS, Dai BD, et al.Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism[J].Fungal Genet Biol,2009,46:183-189. |
|
[29]
|
Clancy CJ, Wingard JR, Hong-Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients:review of the literature and demonstration of invitro synergy between antifungal agents[J].Med Mycol, 2000, 38(2):169-175. |
|
[30]
|
Ellis M, Watson R, McNabb A,et al. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery[J].J Med Microbiol,2002, 51(1):70-75. |
点击查看大图
下载:
